Kaole Bwalya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kaole Bwalya has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Chileleko Siakabanze
Department of Pathology and Microbiology, Mulungushi University, Livingstone, Zambia
3 shared publicationsBenson M Hamooya
Mulungushi University, School of Medicine and Health Sciences, Livingstone, Zambia
2 shared publications- Emmanuel Luwaya
School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia
2 shared publications Sepiso K Masenga
Mulungushi University, School of Medicine and Health Sciences, Livingstone, Zambia
2 shared publicationsAgness Mushabati
Department of Disease Control, The University of Zambia, School of Veterinary Medicine, Lusaka, Zambia
1 shared publicationAlan Kachuka
Department of Public Health, National TB and Leprosy Program, Lusaka, Zambia
1 shared publication
Latest Publications
- 22 October 2026
- Published by Pan African Medical Journal in Pan African Medical Journal
Effectiveness of oral cholera vaccines in controlling outbreaks: a matched case-control study in Luapula Province, Zambia
Introduction: Oral Cholera Vaccines (OCV) are widely used to prevent and control cholera. In 2021, Zambia conducted an oral cholera vaccination campaign in the cholera-endemic districts of Nchelenge, Chiengi, and Mwansabombwe in Luapula Province. In 2023, these same districts experienced a significant cholera outbreak, less than two years later. This study assessed cholera incidence by vaccination status, dose-completion effectiveness, and associated factors. Methods: a quantitative matched case-control study was utilised, enrolling 254 participants (127 cholera cases and 127 matched controls). Cases and controls were matched by location of residence. Data were extracted retrospectively from medical records. Vaccine effectiveness was calculated as (1 - OR). Multivariable conditional logistic regression was the primary analytical method for matched exposure comparisons. Results: in the matched analysis, receipt of at least one dose of OCV was strongly associated with 97.1% lower odds of cholera (OR = 0.029; 95% CI: 0.006 - 0.088; p < 0.001); Two-dose completion was strongly associated with 98.1% lower odds of cholera compared with receipt of a single dose (OR = 0.013, 95% CI: 0.001 - 0.265; p < 0.001); after adjusting for age and sex. Water source analysis among cases and controls showed a significant difference in drinking water source, supporting the continued importance of WASH-related exposure. Conclusion: the oral cholera vaccine provides significant protection against cholera. However, suboptimal two-dose coverage and ongoing exposure to unsafe water sources perpetuate outbreaks. To enhance cholera control, Zambia should prioritise complete two-dose vaccination and integrated water, sanitation, and hygiene (WASH) interventions.
- 22 October 2026
- Published by Pan African Medical Journal in Pan African Medical Journal
Effectiveness of oral cholera vaccines in controlling outbreaks: a matched case-control study in Luapula Province, Zambia
Introduction: Oral Cholera Vaccines (OCV) are widely used to prevent and control cholera. In 2021, Zambia conducted an oral cholera vaccination campaign in the cholera-endemic districts of Nchelenge, Chiengi, and Mwansabombwe in Luapula Province. In 2023, these same districts experienced a significant cholera outbreak, less than two years later. This study assessed cholera incidence by vaccination status, dose-completion effectiveness, and associated factors. Methods: a quantitative matched case-control study was utilised, enrolling 254 participants (127 cholera cases and 127 matched controls). Cases and controls were matched by location of residence. Data were extracted retrospectively from medical records. Vaccine effectiveness was calculated as (1 - OR). Multivariable conditional logistic regression was the primary analytical method for matched exposure comparisons. Results: in the matched analysis, receipt of at least one dose of OCV was strongly associated with 97.1% lower odds of cholera (OR = 0.029; 95% CI: 0.006 - 0.088; p < 0.001); Two-dose completion was strongly associated with 98.1% lower odds of cholera compared with receipt of a single dose (OR = 0.013, 95% CI: 0.001 - 0.265; p < 0.001); after adjusting for age and sex. Water source analysis among cases and controls showed a significant difference in drinking water source, supporting the continued importance of WASH-related exposure. Conclusion: the oral cholera vaccine provides significant protection against cholera. However, suboptimal two-dose coverage and ongoing exposure to unsafe water sources perpetuate outbreaks. To enhance cholera control, Zambia should prioritise complete two-dose vaccination and integrated water, sanitation, and hygiene (WASH) interventions.
- Open Access
- 11 November 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (11) , e0313484
Association between complete blood-count-based inflammatory scores and hypertension in persons living with and without HIV in Zambia
Background: Hypertension is a risk factor for cardiovascular events. Inflammation plays an important role in the development of essential hypertension. Studies assessing the association between complete blood count-based inflammatory scores (CBCIS) and hypertension are scarce. Therefore, this study aimed to determine the relationship between CBCIS and hypertension among individuals with and without human immunodeficiency virus (HIV). Method: This was a cross-sectional study among 344 participants at Serenje District Hospital and Serenje Urban Clinic. We used structured questionnaires to collect sociodemographic, clinical and laboratory characteristics. CBCIS included lymphocyte-monocyte ratio (LMR), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), derived neutrophil-lymphocyte ratio (d-NLR), and differential white blood cells. The primary outcome variable was hypertension defined as systolic and diastolic blood pressure higher than or equal to 140/90 mmHg. Logistic regression was used to estimate the association between hypertension and CBCIS in statistical package for social science (SPSS) version 22.0. Results: The participants had a median age of 32 years (interquartile range (IQR) 24–42) and 65.1% (n = 224) were female. The prevalence of hypertension was 10.5% (n = 36). Among those with hypertension, 55.6% (n = 20) were female and 44.4% (n = 16) were male. The CBCIS significantly associated with hypertension in people living with HIV (PLWH) was PLR (adjusted odds ratio (AOR) 0.98; 95% confidence interval (CI) 0.97–0.99, p = 0.01) while in people without HIV, AMC (AOR 15.40 95%CI 3.75–63.26), ANC (AOR 1.88 95%CI 1.05–3.36), WBC (AOR 0.52 95%CI 0.31–0.87) and PLR (AOR 0.98 95%CI 0.97–0.99) were the factors associated with hypertension. Compared to people without HIV, only WBC, ANC, NLR, and d-NLR were good predictors of hypertension among PLWH. Conclusion: Our study indicates a notable HIV-status driven association between CBCIS and hypertension, suggesting the use of CBICS as potential biomarkers for hypertension risk with substantial implications for early detection and preventive measures.
- 11 November 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (11) , e0313484
Open AccessAssociation between complete blood-count-based inflammatory scores and hypertension in persons living with and without HIV in Zambia
Background: Hypertension is a risk factor for cardiovascular events. Inflammation plays an important role in the development of essential hypertension. Studies assessing the association between complete blood count-based inflammatory scores (CBCIS) and hypertension are scarce. Therefore, this study aimed to determine the relationship between CBCIS and hypertension among individuals with and without human immunodeficiency virus (HIV). Method: This was a cross-sectional study among 344 participants at Serenje District Hospital and Serenje Urban Clinic. We used structured questionnaires to collect sociodemographic, clinical and laboratory characteristics. CBCIS included lymphocyte-monocyte ratio (LMR), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), derived neutrophil-lymphocyte ratio (d-NLR), and differential white blood cells. The primary outcome variable was hypertension defined as systolic and diastolic blood pressure higher than or equal to 140/90 mmHg. Logistic regression was used to estimate the association between hypertension and CBCIS in statistical package for social science (SPSS) version 22.0. Results: The participants had a median age of 32 years (interquartile range (IQR) 24–42) and 65.1% (n = 224) were female. The prevalence of hypertension was 10.5% (n = 36). Among those with hypertension, 55.6% (n = 20) were female and 44.4% (n = 16) were male. The CBCIS significantly associated with hypertension in people living with HIV (PLWH) was PLR (adjusted odds ratio (AOR) 0.98; 95% confidence interval (CI) 0.97–0.99, p = 0.01) while in people without HIV, AMC (AOR 15.40 95%CI 3.75–63.26), ANC (AOR 1.88 95%CI 1.05–3.36), WBC (AOR 0.52 95%CI 0.31–0.87) and PLR (AOR 0.98 95%CI 0.97–0.99) were the factors associated with hypertension. Compared to people without HIV, only WBC, ANC, NLR, and d-NLR were good predictors of hypertension among PLWH. Conclusion: Our study indicates a notable HIV-status driven association between CBCIS and hypertension, suggesting the use of CBICS as potential biomarkers for hypertension risk with substantial implications for early detection and preventive measures.
- Open Access
- 6 September 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (9) , e0308869
Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia
Background: An increase in the prevalence of HIV drug resistance (HIVDR) has been reported in recent years, especially in persons on non-nucleoside reverse transcriptase inhibitors (NNRTIs) due to their low genetic barrier to mutations. However, there is a paucity of epidemiological data quantifying HIVDR in the era of new drugs like dolutegravir (DTG) in sub-Saharan Africa. We, therefore, sought to determine the prevalence and correlates of viral load (VL) suppression in adult people with HIV (PWH) on a fixed-dose combination of tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) or tenofovir alafenamide/emtricitabine/dolutegravir (TAFED) and describe patterns of mutations in individuals failing treatment.Methods: We conducted a cross-sectional study among 384 adults living with HIV aged ≥15 years between 5thJune 2023 and 10thAugust 2023. Demographic, laboratory and clinical data were collected from electronic health records using a data collection form. Viral load suppression was defined as plasma HIV-1 RNA VL of <1000 copies/ml after being on ART for ≥ 6 months. SPSS version 22 to analyze the data. Descriptive statistics and logistic regression were the statistical methods used.Results: The median (interquartile range (IQR)) age was 22 (IQR 18, 38) years, and 66.1% (n = 254) were females. VL suppression was 90.4% (n = 347); (95% confidence interval (CI) 87.6%-93.6%) after switching to TLD/TAFED. Among the virally suppressed, the majority (67.1%, n = 233) were female. Those who missed ≥2 doses in the last 30 days prior to the most recent review were less likely to attain viral suppression compared to those who did not miss any dose (adjusted odds ratio (AOR) 0.047; 95% CI 0.016–0.136; p<0.001). Four participants had resistance mutations to lamivudine and tenofovir. The most common NRTI mutations were M184MV and K65R while K101E was the most common NNRTI mutation.Conclusion: Our findings show that viral suppression was high after switching to TLD/TAFED; but lower than the last 95% target of the UNAIDS. Adherence to antiretroviral therapy was a significant correlate of VL suppression. We, therefore, recommend prompt switching of PWH to TLD/TAFED regimen and close monitoring to enhance adherence to therapy.
- 6 September 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (9) , e0308869
Open AccessViral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia
Background: An increase in the prevalence of HIV drug resistance (HIVDR) has been reported in recent years, especially in persons on non-nucleoside reverse transcriptase inhibitors (NNRTIs) due to their low genetic barrier to mutations. However, there is a paucity of epidemiological data quantifying HIVDR in the era of new drugs like dolutegravir (DTG) in sub-Saharan Africa. We, therefore, sought to determine the prevalence and correlates of viral load (VL) suppression in adult people with HIV (PWH) on a fixed-dose combination of tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) or tenofovir alafenamide/emtricitabine/dolutegravir (TAFED) and describe patterns of mutations in individuals failing treatment.Methods: We conducted a cross-sectional study among 384 adults living with HIV aged ≥15 years between 5thJune 2023 and 10thAugust 2023. Demographic, laboratory and clinical data were collected from electronic health records using a data collection form. Viral load suppression was defined as plasma HIV-1 RNA VL of <1000 copies/ml after being on ART for ≥ 6 months. SPSS version 22 to analyze the data. Descriptive statistics and logistic regression were the statistical methods used.Results: The median (interquartile range (IQR)) age was 22 (IQR 18, 38) years, and 66.1% (n = 254) were females. VL suppression was 90.4% (n = 347); (95% confidence interval (CI) 87.6%-93.6%) after switching to TLD/TAFED. Among the virally suppressed, the majority (67.1%, n = 233) were female. Those who missed ≥2 doses in the last 30 days prior to the most recent review were less likely to attain viral suppression compared to those who did not miss any dose (adjusted odds ratio (AOR) 0.047; 95% CI 0.016–0.136; p<0.001). Four participants had resistance mutations to lamivudine and tenofovir. The most common NRTI mutations were M184MV and K65R while K101E was the most common NNRTI mutation.Conclusion: Our findings show that viral suppression was high after switching to TLD/TAFED; but lower than the last 95% target of the UNAIDS. Adherence to antiretroviral therapy was a significant correlate of VL suppression. We, therefore, recommend prompt switching of PWH to TLD/TAFED regimen and close monitoring to enhance adherence to therapy.